

Lung Cancer Driver Mutations in Non-Small Cell Lung Cancer



Charles N. Prabhakar

Faculty of Medicine

The University of Sydney

A thesis submitted for the degree of

Master of Philosophy (Medicine)

Yet to be decided

Contents

Contents	i
List of Figures	ii
List of Tables	iii
1 Lung Cancer	1
1.1 See Steven's email 22/10/15	1
1.2 Epidemiology	1
1.3 Aetiology	2
1.4 Histopathology	2
1.5 Mutation	3
1.5.1 EGFR	3
1.5.2 KRAS	5
1.5.3 ALK / ROS1 Rearrangement	5
1.6 Prognosis	5
1.6.1 Early Stage	5
1.6.2 Late Stage	6
1.7 Diagnosis	6
1.7.1 Radiology	6
1.7.2 Tissue Obtaining	6
1.8 Tissue analysis	7
1.8.1 current methods	7
1.8.2 next gen sequencing	7
Bibliography	8

List of Figures

1.1 Lung Cancer Incidence in Australia, 1982 - 2011	2
---	-------------------

List of Tables

Nomenclature

Roman Symbols

COSMIC Catalogue of Somatic Mutations in Cancer

DFS disease free survival

EGF Epidermal Growth Factor

EGFR Epidermal Growth Factor Receptor

LCC large cell carcinoma

NSCLCa non-small cell lung cancer

OS overall survival

SCLCa small cell lung cancer

SqCC squamous cell carcinoma

TKI Tyrosine Kinase Inhibitors

Chapter 1

Lung Cancer

1.1 See Steven's email 22/10/15

1.2 Epidemiology

Lung cancer is a disease with an ever increasing global burden, contributing to more than 1.5 million deaths world wide in 2010¹ and 2.5 million new diagnoses² with an incidence of nearly 500 per 100000³. Traditionally, lung cancer has a far higher incidence amongst men than women, however in Australia, from 1982 - 2011 that difference has diminished from over 4 fold to under 2 fold (Fig. 1.1)⁴. This change is due, not only to the falling incidence of lung cancer amongst men, but also to the rising incidence amongst women.




Figure 1.1: Lung Cancer Incidence in Australia, 1982 - 2011

1.3 Aetiology

In 1964, it was first recognised that cigarette smoke was casually related to lung cancer, with a report to the Surgeon General of America concluding "the magnitude of the effect of cigarette smoking [on lung cancer] far outweighs all other factors"⁵. The changing incidence in lung cancer reflects the current Australian societal trend in falling smoking prevalence, amongst both men and women. In 1980 41 % of men and 30 % of women were classified as regular smokers (smoking at least weekly), nearly converging at 22 % and 18 %, respectively, in 2010⁶.

1.4 Histopathology

Previously lung cancer was simply divided in to non-small cell lung cancer (NSCLCa) and small cell lung cancer (SCLCa), but as the understanding of lung cancer has developed is now possible, and required, to further differentiate lung cancer in to the various distinct but related subtypes.

Approximately 85 % of lung cancers are NSCLCa⁷ which can then be subsequently further divided in to the following three major distinct histological subtypes⁸; adenocarcinoma, squamous cell carcinoma (SqCC) and large cell carcinoma (LCC). From 1980 to 1997 a shift in NSCLCa histopathologies was identified with an increase in the incidence of adenocarcinomas and a fall in the incidence of squamous cell carcinoma⁹.

1.5 Mutation

All malignancies are thought to arise from a single or series of genetic mutations which then confer an ability to replicate in an uncontrolled manner. In 2004 it was identified that 10 % of patients with NSCLCa will have a, potentially dramatic, response to tyrosine kinase inhibitors (TKI)¹⁰. Since then the Catalogue of Somatic Mutations in Cancer (COSMIC)¹ database¹¹ lists over 26000 different mutations, with 4600 having a frequency of greater than 1 %.

Since then 145 genes have been identified as potential lung cancer driver mutations¹², however only a few currently possess commercially available therapeutic drugs.

1.5.1 EGFR

The Epidermal Growth Factor Receptor (EGFR) is a 170 kdalton member of the ErbB family of cell surface tyrosine kinases¹³, and is encoded on chromosome 7. The receptor belongs to the HER/erbB family of tyrosine kinases, which include

¹<http://cancer.sanger.ac.uk/cosmic>

HER1 (EGFR/erbB1), HER2 (neu, erbB2), HER3 (erbB3) and HER4 (erbB4)¹⁴.

The EGFR is made of up three portions; an extracellular ligand binding domain, a transmembrane domain and an intracellular tyrosine kinase domain^{15,16}. Activation of the protein is achieved by binding of a ligand (such as epidermal growth factor, transforming growth factor- α and neuregulins¹⁶) to the extracellular domain. Once a ligand is bound to the extracellular domain, the receptor undergoes dimerisation or heterodimerisation with related receptors (especially HER2/neu¹⁷). Without the aforementioned ligand binding and subsequent dimerisation, there is no intrinsic activity of the tyrosine kinase portion of the receptor¹⁶.

The tyrosine kinase portion of the receptor is normally in a state of autoinhibition, but on dimerisation there is rapid autophosphorylation of the intracellular tyrosine residues. The phosphorylated then functions to allow assembly and activation of intracellular messenger proteins^{18,19}, especially through the mammalian target of rapamycin (mTOR)²⁰.

In 1984 Gill *et al* demonstrated that EGFR blockade with a chimeric anti-EGFR antibody, in human epidermoid carcinoma cell lines expressing EGFR, resulted in a reduction in auto-phosphorylation²¹. A similar study by Kawamoto *et al* revealed a biphasic cell proliferation response to the same cells exposed to Epidermal Growth Factor (EGF); with cellular proliferation at low levels of EGF and inhibition at higher levels. Taken together, this was felt to demonstrate that in human epidermoid malignancies EGFR expression and activation played a role in cancer proliferation.

Over expression of *EGFR* (?need to add gene here) has been identified in a variety of cancers including: head and neck, ovarian, bladder, oesophageal, gastric, brain, breast, endometrial, colonic and lung²². In NSCLCa, *EGFR* overexpression has been identified in 41 % of adenocarcinomas¹⁰ and 89 % of squamous cell carcinomas (SqCCa)²³.

1.5.1.1 T790M

1.5.2 KRAS

1.5.3 ALK / ROS1 Rearrangement

1.6 Prognosis

1.6.1 Early Stage

Surgery for early NSCLCa provides a potentially curative management strategy. However, even for those patients who receive curative intent surgical resection, followed by optimal adjuvant chemotherapy (when appropriate) will only receive an absolute overall survival (OS) advantage of 5.4 % at 5 years and an improvement in disease free survival of 5.8 %²⁴. This equates to a 5 year survival rate for NSCLCa, depending pathological stage, from 25 % to 73 %²⁵.

1.6.2 Late Stage

However, over 75 % of patients with new NSCLCa diagnoses will present with an advanced stage²⁶, and will not be eligible for curative intent treatment. Those presenting thusly will have a median survival of only 119 days²⁷ without chemotherapy. Even those patients who are suitable to receive conventional chemotherapy, an overall survival of only about 8 months is achievable with a response rate of only 19 % achievable²⁸.

1.7 Diagnosis

Foobar²⁸.

1.7.1 Radiology

1.7.2 Tissue Obtaining

Difficultly obtaining tissue Earlier diagnosis == smaller nodules Smaller tissue == less to analyse == less DNA to use

1.8 Tissue analysis

1.8.1 current methods

1.8.2 next gen sequencing

Bibliography

1. Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;380:2095–2128.
2. Jemal, A, Siegel, R, Ward, E, et al. *Cancer Statistics, 2008*. CA: a cancer journal for clinicians 2008;58:71–96.
3. Boyle, P and Levin, B. *World Cancer Report 2008*. World Health Organization, 2008.
4. Australian Institute of Health and Welfare. *Australian Cancer Incidence and Mortality (ACIM) books. Lung Cancer*. 2015.
5. Advisory Committee to the Surgeon General of the Public Health Service, R of the. *Smoking and Health*. US Department of Health, Education and Welfare. 1976.
6. Scollo, MM and Winstanley, MH. *Tobacco in Australia. Facts and Issues*. Cancer Council Victoria, 2013.

BIBLIOGRAPHY

7. Herbst, RS, Heymach, JV, and Lippman, SM. Lung cancer. The New England journal of medicine 2008;359:1367–1380.
8. Travis, WD. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Diamond Pocket Books (P) Ltd., 2004.
9. Devesa, SS, Bray, F, Vizcaino, AP, and Parkin, DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. International journal of cancer. Journal international du cancer 2005;117:294–299.
10. Lynch, TJ, Bell, DW, Sordella, R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. The New England journal of medicine 2004;350:2129–2139.
11. Forbes, SA, Beare, D, Gunasekaran, P, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic acids research 2015;43:D805–11.
12. Chen, Y, Shi, JX, Pan, XF, Feng, J, and Zhao, H. Identification of candidate genes for lung cancer somatic mutation test kits. Genetics and molecular biology 2013;36:455–464.
13. Cadranel, J, Ruppert, AM, Beau-Faller, M, and Wislez, M. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Critical reviews in oncology/hematology 2013;88:477–493.
14. Cunha Santos, G da, Shepherd, FA, and Tsao, MS. EGFR mutations and lung cancer. Annual Review of Pathology: Mechanisms of Disease 2011;6:49–69.

BIBLIOGRAPHY

15. Krause, DS and Van Etten, RA. Tyrosine kinases as targets for cancer therapy. *The New England journal of medicine* 2005;353:172–187.
16. Yarden, Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. *European journal of cancer (Oxford, England : 1990)* 2001;37 Suppl 4:S3–8.
17. Tzahar, E, Waterman, H, Chen, X, et al. A hierarchical network of inter-receptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. *Molecular and cellular biology* 1996;16:5276–5287.
18. Lemmon, MA and Schlessinger, J. Cell signaling by receptor tyrosine kinases. *Cell* 2010;141:1117–1134.
19. Cohen, S, Carpenter, G, and King, L. Epidermal growth factor-receptor-protein kinase interactions. *Progress in clinical and biological research* 1981;66 Pt A:557–567.
20. Siegelin, MD and Borczuk, AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. *Laboratory investigation; a journal of technical methods and pathology* 2014;94:129–137.
21. Gill, GN, Kawamoto, T, Cochet, C, Le, A, and Sato, JD. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor ... *Journal of Biological ...* 1984;259:7755–7760.
22. Sharma, SV, Bell, DW, Settleman, J, and Haber, DA. Epidermal growth factor receptor mutations in lung cancer. *Nature reviews. Cancer* 2007;7:169–181.

BIBLIOGRAPHY

23. Al Olayan, A, Al Hussaini, H, and Jazieh, AR. The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer. *Journal of infection and public health* 2012;5 Suppl 1:S50–60.
24. Pignon, JP, Tribodet, H, Scagliotti, GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *Journal of Clinical Oncology* 2008;26:3552–3559.
25. Goldstraw, P, Ball, D, Jett, JR, et al. Non-small-cell lung cancer. *Lancet* 2011;378:1727–1740.
26. Slatore, CG, Gould, MK, Au, DH, Deffebach, ME, and White, E. Lung cancer stage at diagnosis: Individual associations in the prospective VITamins and lifestyle (VITAL) cohort. *BMC cancer* 2011;11:228.
27. Rapp, E, Pater, JL, Willan, A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer—report of a Canadian multicenter randomized trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 1988;6:633–641.
28. Schiller, JH, Harrington, D, Belani, CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *The New England journal of medicine* 2002;346:92–98.